Survival for testicular cancer has risen by almost 30 per cent in the last 40 years, with nearly all men now beating the disease, according to figures published by Cancer Research UK.

These latest figures show that more than 96 per cent of men now survive testicular cancer in the UK, compared with less than 70 per cent in the 1970s. These improvements are largely thanks to the drug cisplatin, which Cancer Research UK helped to develop.

czytaj więcej

The taller a postmenopausal woman is, the greater her risk for developing cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

czytaj więcej

A family history of cancer increases the risk of other members of the family developing not only the same cancer (known as a concordant cancer) but also a different (discordant) cancer, according to a large study of 23,000 people in Italy and Switzerland.

The research, published in the leading cancer journal Annals of Oncology, provides a comprehensive picture of the risk of developing various different types of cancer in families where there is a history of the disease, and is one of the few large studies of this kind that takes into account other important factors, such as individual characteristics and lifestyles, that could affect the degree of risk as well.

czytaj więcej

Cancer Research UK scientists have identified a link between higher levels of sex hormones and an increased risk of breast cancer in premenopausal women, according to a study published in The Lancet Oncology.

czytaj więcej

Scientists have identified a protein that could play a crucial role in recognising whether bowel cancer patients need chemotherapy as there is a high risk of their bowel cancer spreading, according to a new study published in the British Journal of Cancer

czytaj więcej

A radioactive drug can improve survival rates in men whose prostate cancer has spread to their bones, as well improve their quality of life, UK research has confirmed.

The injection of radium-223 delivers high-energy radiation to cancer cells in the bone. The so-called 'alpha-pharmaceutical' treatment has recently been approved by the FDA in America for men with treatment-resistant prostate cancer and is being assessed by NICE in the UK, with a decision expected early next year.

czytaj więcej

Cancer researchers have wondered why ovarian cancer cells are so attracted to the abdominal cavity, especially the omentum, with the hope that such an understanding could lead to better disease management or even prevention.

Results from a series of experiments suggest a two-step model of omental colonization in which i) cancer cells are attracted to and lodge within immune cell-containing structures known as milky spots, and ii) fat storage cells (adipocytes) fuel cancer cell growth and spread.

This study is published in The American Journal of Pathology.

czytaj więcej

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.

According to data published in The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies.

czytaj więcej

In a world first, a new Cancer Research UK study will unlock lung cancer’s secrets, tracking in real time how lung tumours develop and evolve as patients receive treatment.

In one of the largest ever studies of lung cancer patients globally, this pioneering project will examine exactly how lung cancers mutate, adapt and become resistant to treatments.

czytaj więcej

An ingenious new treatment for advanced prostate cancer, which homes in on tumours to deliver a high-energy burst of radiation to cancer cells, has shown significant benefits to patients in a large-scale clinical trial.

The results of the phase III trial of 921 patients, published in the New England Journal of Medicine, show that treatment with radioactive radium-223 gave men with late-stage prostate cancer an average extra 3.6 months – about 15 weeks – of life.

czytaj więcej